Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:23 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma
NCT05255601 · Bristol-Myers Squibb · PHASE1/PHASE2 · terminated · last registry update 2026-06-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Bristol-Myers Squibb |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against LAG3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-03Also stopped (suspended): National Cancer Institute (NCI), Lomustine + Nivolumab (NCT06325683)
- 2026-11-03Results posted on the registry: Columbia University, Gemcitabine + Cisplatin (NCT06571708)
- 2026-11-03Also stopped (terminated): Columbia University, Gemcitabine + Cisplatin (NCT06571708)
- 2026-10-28Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Nivolumab + Relatlimab (NCT04658147)
- 2026-10-19Also stopped (suspended): National Cancer Institute (NCI), a drug against LAG3 (NCT04866810)
- 2026-10-14Results posted on the registry: Bristol-Myers Squibb, Relatlimab + Nivolumab (NCT05337137)
- 2026-09-14Also stopped (withdrawn): Virginia Commonwealth University, Arm 1 cemiplimab + Arm 2 cemiplimab and fianlimab (NCT07365839)
- 2026-09-03Also stopped (withdrawn): Memorial Sloan Kettering Cancer Center, Cemiplimab + Cemiplimab and Fianlimab (NCT07414992)
- 2026-09-01Results posted on the registry: Merck Sharp & Dohme LLC, favezelimab/pembrolizumab + bendamustine (NCT05508867)
- 2026-08-31Results posted on the registry: John Kirkwood, Relatlimab + Nivolumab (NCT03743766)
- 2026-08-31Also stopped (terminated): Merck Sharp & Dohme LLC, Pembrolizumab + Pembrolizumab/vibostolimab coformulation (NCT02625961)
- 2026-08-27Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Vibostolimab (NCT04303169)
- 2026-08-26Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Relatlimab + rHuPH20 (NCT05625399)
- 2026-08-26Results posted on the registry: Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2026-08-26Also stopped (terminated): Bristol-Myers Squibb, Nivolumab-relatlimab FDC + Regorafenib (NCT05328908)
- 2026-07-30Also stopped (terminated): Immutep S.A.S., eftilagimod alpha + Paclitaxel (NCT05747794)
- 2026-07-28Also stopped (terminated): Merck Sharp & Dohme LLC, pembrolizumab + Favezelimab (NCT03598608)
- 2026-07-02Also stopped (withdrawn): National Health Research Institutes, Taiwan, Nivolumab + Gemcitabine (NCT07369791)
- 2026-06-10Also stopped (suspended): Thomas Jefferson University, Cemiplimab + Fianlimab (NCT05929664)
- 2026-06-08Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Pembrolizumab/Quavonlimab (NCT04895722)
- 2026-06-08Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Favezelimab (NCT03516981)
- 2026-05-15Also stopped (terminated): Iovance Biotherapeutics, Inc., Lifileucel + LN-145 (NCT03645928)
- 2026-04-09Results posted on the registry: Bristol-Myers Squibb, relatlimab+nivolumab + relatlimab+nivolumab+rHuPH20 (NCT06101134)
- 2026-04-06Results posted on the registry: Bristol-Myers Squibb, Relatlimab + Nivolumab (NCT03459222)
- 2026-01-08Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Nivolumab + Relatlimab Fixed Dose Combination (NCT05002569)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision